A Career Built on Science, Service and Straight-Talk.

I’m Chad Dumstorf, M.S., Ph.D., a biomedical scientist, scientific communicator, and founder of DumstorfAI™. I bring more than twenty years of scientific training, research, and field medical experience to one purpose: turning complex science into clear understanding that earns trust and supports defensible decisions. 

My foundation was built in the U.S. Navy, where I learned precision, accountability, and the importance of communicating clearly when the stakes are high. Those habits stayed with me, and they define the standard I bring into every project and collaboration.

I earned my M.S. and Ph.D. in Pharmacology & Toxicology at the University of Louisville School of Medicine, followed by a multi-year postdoctoral fellowship at Eli Lilly & Company, where I sharpened the scientific judgment, communication instincts, and problem-solving discipline I still rely on today.

Since then, I’ve served across oncology, medical affairs, and translational research, reading the complex, extracting the signal and making it understandable for physicians, pharma teams, and decision makers who don’t have time for confusion.

As an Independent Medical Science Liaison (IMAC™), I support Medical Affairs teams with disciplined scientific communication, evidence interpretation, and liaison-level judgment, using tools where appropriate and restraint where accuracy and accountability matter more than speed 

I also hold Quality Matters™ certifications in online teaching and accessibility, which shapes how I design and deliver scientific communication, emphasizing clarity, structure, and accessibility across all audiences, devices, and learning environments.

Research & Publications

My research spans pharmacology, cancer biology, translational research, experimental therapeutics, and scientific interpretation governance. My published work includes research conducted at the University of Louisville, Lilly Research Laboratories, and Wood Hudson Cancer Research Laboratory, alongside more recent scholarship through DumstorfAI™. 

Peer-Reviewed Journal Publications

Participation of Mouse DNA Polymerase ι in Strand-Biased Mutagenic Bypass of UV Photoproducts and Suppression of Skin Cancer
Proceedings of the National Academy of Sciences, 2006 | First Author

Targeting the eIF4F Translation Initiation Complex for Cancer Therapy
Cell Cycle, 2008

REV1 Is Implicated in the Development of Carcinogen-Induced Lung Cancer
Molecular Cancer Research, 2009 | First Author

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
Cancer Research, 2009

Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis
Molecular Cancer Therapeutics, 2010 | First Author

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases
Cancer Research, 2011

Conference Publications & Research Abstracts

Abstract LB-384: Elevated eIF4E Phosphorylation Is Associated with Advanced Malignancy and Decreased Patient Survival and Can Be Therapeutically Inhibited by a Novel, Orally Bio-Available Mnk Inhibitor
Cancer Research, 2011

Abstract A237: Elevated Mnk Kinase Activity Is Associated with Malignant Progression and Reduced Patient Survival in Human Prostate Cancer and Can Be Therapeutically Inhibited by the Novel, Orally Bioavailable Mnk Inhibitor Cercosporamide
Molecular Cancer Therapeutics, 2011

Disruption of the eIF4F Translation Initiation Complex as a Determinant of Diffuse Large B-Cell Lymphoma Responsiveness to Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020)
Journal of Clinical Oncology, 2012

Abstract LB-235: Sensitivity of Diffuse Large B Cell Lymphoma Cells to Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020) Is Critically Dependent upon Disruption of the eIF4F Translation Initiation Complex
Cancer Research, 2012

489 Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020.HCl) Exert Antitumor Effects in Diffuse Large B Cell Lymphoma Through Multiple Mechanisms, Most Notably Control of 4EBP1 Activity
European Journal of Cancer, 2012

The Direct Anti-Tumor Activity of Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020.HCl) Is Evident in Preclinical DLBCL Models Regardless of Molecular Subtype
Blood, 2012

Abstract LB-302: eIF4E Phosphorylation Is Mnk-Dependent but Does Not Require Assembly of the eIF4F Translation Initiation Complex
Cancer Research, 2014

Abstract 3919: Phosphorylation of eIF4E Is a Critical Factor in Development and Progression of Breast Cancer in Women
Cancer Research, 2016 | First Author

AI Governance and Scientific Interpretation

The Unowned Layer: Interpretation in AI-Assisted Decision Making
SSRN, 2026

The Unowned Layer in Practice: How Decisions Drift in AI-Assisted Workflows Without Governance
SSRN, 2026

— HONOR THE SCIENCE ✕ RESPECT THE TRUTH ✕ SERVE WITH CLARITY —
The same way I learned to serve — with discipline, integrity, and purpose.